Versatile pharmacological actions of YC-1: anti-platelet to anticancer.
Since the first article on YC-1 was published in 1994, it has been popularly used as a pharmacological tool to activate soluble guanylate cyclase and to increase cyclic GMP levels in cultured cells or isolated tissues. In terms of the pharmacological actions of YC-1, previous studies tend to be limited to it inhibition of platelet aggregation and vascular concentration. However, recent studies have demonstrated that YC-1 has versatile pharmacological effects other than the anti-platelet and vasodilatory effects. In particular, two recent reports suggest that YC-1 could be developed as a new class of anticancer agent for rapidly growing solid tumors, because it inhibits hypoxia-inducible factor 1 (HIF-1) activity, and has been reported to halt tumor growth in vivo. We here review the cyclic GMP-dependent and independent pharmacological actions of YC-1, and its anti-HIF-1, anticancer effect.
Chun
Yang-Sook
YS
Human Genome Research Institute and Cancer Research Institute, Seoul National University College of Medicine, South Korea.
Yeo
Eun-Jin
EJ
Park
Jong-Wan
JW
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D006152:Cyclic GMP / Q000378:metabolism; D006162:Guanylate Cyclase / Q000378:metabolism; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D007191:Indazoles / Q000494:pharmacology*; D009369:Neoplasms / Q000473:pathology / Q000628:therapy; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D014157:Transcription Factors / Q000096:biosynthesis
D000970:Antineoplastic Agents; C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D007191:Indazoles; D010975:Platelet Aggregation Inhibitors; D014157:Transcription Factors; C090937:3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole; D006162:Guanylate Cyclase; D006152:Cyclic GMP